GARFIELD: A window on the real-life treatment of atrial fibrillation - South Africa joins the GARFIELD registry

摘要

The .results of the evaluation of ihe first cohort of 10 000 newly diagnosed atrial fibrillation (AF) patients in the GARF1ELD registry, which reflects contemporary global real-life treatment of AF, has shown that fewer than half of the eligible patients received anticoagulant therapy with vitamin K antagonists. In addition, those patients at significantly increased risk of experiencing stroke or systemic emboli with a CHADS, risk score greater than 2 were poorly treated. Patients who were not really at risk (those with a CHADS, score of zero) and who did not generally require anticoagulation treatment were frequently given anticoagulant therapy in some 80% of cases. The GARFIELD (Global Anticoagulant Registry in the FIELD) seeks better understanding of these contradictions in an academically driven project, led by the UK-based Thrombosis Research Institute and funded with an unrestricted grant from Bayer Healthcare.